Track topics on Twitter Track topics that are important to you
Evaluation of Health Related Quality of Life (HRQL) is of a paramount importance in assessing the impact of Rheumatoid Arthritis on patients' health status, however when costs associated with Rheumatoid Arthritis are also taken into account, the information provided may lead to a more balanced view in analyzing the treatment of the disease.
In accordance with the above, the main objective of our study will be to evaluate the impact of Adalimumab treatment not only on patients' Health Related Quality of Life but also on the cost of the disease management. In order to accomplish that we will focus on:
1. Estimating the cost and specifically the direct and indirect cost incurred by Adalimumab treatment.
2. Measuring the Health Related Quality of Life of Rheumatoid Arthritis patients under Adalimumab treatment.
3. Exploring the cost-utility relationship of Rheumatoid Arthritis patients treated with Adalimumab by combining the Health Related Quality of Life of Rheumatoid Arthritis patients and direct as well as indirect costs due to RA.
More specifically, data related to patients' Health Related Quality of Life and cost associated with Rheumatoid Arthritis will be recorded for one-year period, and collected at four subsequent visits: baseline, month 3, 6 and 12.As baseline will be considered the visit before starting treatment with Adalimumab.That will contribute at comparing Health Related Quality of Life and cost data before and after Adalimumab initiation and therefore identifying the effect of Adalimumab treatment in patients with Rheumatoid Arthritis.
Data concerning patients' Health Related Quality of Life as well as the cost of the disease treatment will be administrated at four subsequent periods and specifically at baseline (Visit 1), and at months 3, 6 and 12.
Moreover, at baseline patients' socioeconomic, and history of illness data as well as the use of other prescribed medication and costs due to Rheumatoid Arthritis will be recorded, in order to identify patients' health state before Adalimumab treatment initiation.
Patients discontinuing therapy (drop-outs) either due to adverse events or on their own initiative will be categorized and analyzed separately, while reasons leading to discontinuation will be recorded.
In order to evaluate the cost-utility of Adalimumab we will take into account both the cost of the disease treatment and the Health Related Quality of Life of Rheumatoid Arthritis patients. The process, which is intended to be followed is described upon below:
Face-to-face interviews will be conducted by the physicians/investigators in charge in all four subsequent periods as well as before Adalimumab treatment initiation. A questionnaire, designed especially for the objectives of the study and divided into the following sections will be used: 1. Patients' Sociodemographic Characteristics 2. Measurement of Health Related Quality of Life in Rheumatoid Arthritis patients 3. Cost Assessment
Observational Model: Cohort, Time Perspective: Prospective
Site Reference ID/Investigator# 32070
Active, not recruiting
Published on BioPortfolio: 2014-08-27T03:15:34-0400
Primary aim: examine a possible connection between cigarette smoking, disease activity and perceived pain in patients with rheumatoid arthritis. Secondary aim: Evaluate cardiovascular ris...
The purpose of this study is to compare the incidence rates of infection, malignancy and death among patients with rheumatoid arthritis who are treated with abatacept and those who are tre...
Objective: To evaluate what factors contribute to activity limitations in subjects with rheumatoid arthritis considering the International Classification of Functioning, Disability and Hea...
Patients with rheumatoid arthritis are at increased risk of having cardiovascular deaths. Our study is aimed at looking at the effects of proven cholesterol lowering treatment drug called ...
This study will look at whether this new drug is effective in the treatment of rheumatoid arthritis, and at whether it is safe and well-tolerated by patients with the disease.
We would like to thank Masi and colleagues for their interest in our paper as well as for the interesting comments regarding the potential usefulness of neuroendocrine immune (NEI) testing in patients...
Juvenile idiopathic arthritis (JIA) is comprised of seven heterogeneous categories of chronic childhood arthritides. About 5% of children with JIA have rheumatoid factor (RF) positive arthritis, which...
Rheumatoid arthritis (RA) as an inflammatory autoimmune disease affects the synovial joints as well as other organs and tissues. Since aberrant expression of MIC molecules has been observed in RA pati...
Chikungunya is a rapidly emerging, global viral infection that can cause chronic, debilitating arthritis that in some ways mimics rheumatoid arthritis. This study evaluated the available evidence of t...
To forecast the prevalence and direct healthcare costs of osteoarthritis (OA) and rheumatoid arthritis (RA) in Australia to the year 2030.
Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.
Rheumatoid arthritis of children occurring in three major subtypes defined by the symptoms present during the first six months following onset: systemic-onset (Still's Disease, Juvenile-Onset), polyarticular-onset, and pauciarticular-onset. Adult-onset cases of Still's disease (STILL'S DISEASE, ADULT-ONSET) are also known. Only one subtype of juvenile rheumatoid arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.
A variable mixture of the mono- and disodium salts of gold thiomalic acid used mainly for its anti-inflammatory action in the treatment of rheumatoid arthritis. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis.
Systemic-onset rheumatoid arthritis in adults. It differs from classical rheumatoid arthritis in that it is more often marked by acute febrile onset, and generalized lymphadenopathy and hepatosplenomegaly are more prominent.
Antibodies found in adult RHEUMATOID ARTHRITIS patients that are directed against GAMMA-CHAIN IMMUNOGLOBULINS.
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...